Navigate Up
Launch the Developer Dashboard
IAS 2012 Network Presentations
IAS 2012 took place from July 22-27, 2012 in Washington DC. You can review the program by clicking here.
 

Background on the IAS: The International AIDS Society is the world’s leading independent association of HIV professionals.

The IAS connects the professionals who work in the HIV field by convening the world's foremost international conferences on HIV and AIDS and specialized meetings. The IAS provides critical platforms for presenting new research, promoting dialogue and building consensus to advance the global fight against HIV. The IAS also promotes by promoting dialogue, education and networking, and providing access to best practice, professional development and skills building and builds capacity and close gaps in knowledge and expertise at every level of the HIV response. The IAS mobilizes by advocating for the right to an evidence-based response to HIV and for a concerted resarch effort to build that evidence base, the IAS contributes to continuous improvement of the global response to HIV. For more about the IAS, please visit this page.

The first section details the various satellite sessions taking place at IAS 2012. Below that, you will find network presentations from the IAS 2012 meeting listed in alphabetical order by network. ​

 

 Satellite Sessions

 

​The Role of Vaccines in Ending the Pandemic

3rd Annual Workshop on Global HIV Clinical Pharmacology Capacity Building and Implementation Research

HPTN at the XIX International AIDS Conference Washington, DC

The INSIGHT Network is hosting a Satellite Session: "5 Years After the SMART Study - A Paradigm Shifting Trial".

 

Below are satellite sessions presented by MTN.

Rectal Microbicides: Making HIV Prevention Gel. 

Choice Matters: Expanding the Method Mix of ARV-Based Prevention for Women in 2012 and Beyond.

This is a satellite session presented in partnership with AVAC, IRMA, and the IPM. 

 

Microbicides: The Road Ahead.

This is a satellite session presented by Jeanne Marrazzo which in addition to MTN is being organized by the Population council, IPM, CONRAD, and IRMA. 

 

Latino/Hispanic HIV Community Research Forum: Creando Una Red Para Sin VIH/SIDA.

The International epidemiologic Databases to Evaluate AIDS network will host "Global Cohort Collaborations and the Role of Extremely Large Data Sets in HIV/AIDS and Other Diseases."  

New Frontiers in NIH AIDS Research.  

No "Getting to Zero" without Scale-Up of Stigma Reduction.

 

 ACTG

 

Antiretroviral Therapy Strategies Subcommittee of Cure TSG

Pharmacogenetics of intrapartum single-dose nevirapine (SD NVP) in ACTG protocol A5207.

This is an oral poster presentation authored by D. Haas, E. Acosta, S. Vardhanabhuti, H. Ribaudo, D. Severe, U. Lalloo, N. Kumarasamy, F. Taulo, J. Kabanda, O. Oneko, P. Ive, P. Sambarey, E. Chan, J. Hitti, and D. McMahon. 

 

Associations of inflammatory markers with AIDS and non-AIDS clinical events after initiation of ART: ACTG​ protocol A5202.

This is an oral presentation authored by G. McComsey, D. Kitch, P. Sax, C. Tierney, N. Jahed, K. Melbourne, B. Ha, T. Brown, A. Bloom, N. Fedarko, and E. Daar. 

 

Atazanavir pharmacokinetics and efficacy and safety outcomes by sex in ACTG group study 5202.

This is an oral poster presentation authored by C. Venuto, K. Mollan, Q. Ma, E. Daar, P. Sax, M. Fischl, A. Collier, K. Smith, D. Lu, C. Teirney, and G. Morse. 

 

Tenofovir plasma pharmacokinetics in ACTG A5202.

This is a poster presentation authored by C. Venuto, Q. Ma, E. Daar, P. Sax, M. Fischl, A. Collier, K. Mollan, K. Smith, C. Tierney, and G. Morse. 

 

End-Organ Disease/Inflammation Transformative Science Group

Associations between apolipoprotein L1 plasma levels and APOL1 genetic variants with kidney disease in HIV-1 infected African Americans.

This is a poster presentation authored by R. Kalayjian, M. Ross, J. O'Toole, S. Waikar, S. Madhaven, M. Smurzynski, R. Bosch, S. Gupta, M. Pollak, J. Sedor, and L. Bruggeman. 

 

The interplay of the osteoprotegerin/RANKL axis and dysfunctional HDL in HIV-infected adults. ACTG NWCS 332/A5078 study.

This is an oral presentation authored by T. Kelesidis, M. Kendall, O. Yang, and J. Currier. 

 

Tumor necrosis factor-α soluble receptor type II level is an independent predictor of HIV disease progression after 8 weeks in a clinical endpoint trial (ACTG 320) in advanced HIV infection.

This is a poster presentation authored by J. Spritzler, D. Stein, J. Bilello, L. Poretsky, G. Pakes, and D. Mildvan. 

 

Factors associated with CD8+ T cell activation in HIV-1-infected participants who have been on antiretroviral therapy for ≥ 96 weeks in ACTG studies.

This is a poster presentation authored by L. Zheng, B Taiwo, R. Gandhi, P. Hunt and R. Bosch.

 

Co-Infections and Malignancies Subcommittee of Inflammation TSG

Safety and immunogenicity of the quadrivalent human papillomavirus vaccine in HIV-infected women.

This is an oral presentation authored by E. Kojic, M. Cespedes, T. Umbleja, M. Kang, J. Aberg, R. Allen, B. Grinsztejn, C. Firnhaber, J. Webster-Cyriaque, J. Palefsky, C. Godfrey, A. Saah, and S. Cu-Uvin.

 

Hepatitis Transformative Science Group

The addition of Nitazoxanide to peginterferon alfa-2a and ribavirin does not significantly improve sustained virologic response in HCV treatment-naive genotype 1 HIV-1/HCV co-infected subjects: Results of ACTG 5269.

This is an oral presentation authored by V. Amorosa, T. Umbleja, V. Johnson, M. Kang, A. Luetkemyer, M. Bardin, D. Haas, R. Chung, S. Yesmin, B. Alston-Smith, P. Tebas, and M. Peters.

 

Tuberculosis Transformative Science Group

Relationship between weight, efavirenz (EFV) concentrations and virologic suppression in HIV+ patients on rifampin (RIF)-based TB treatment in the ACTG 5221 STRIDE study.

This is an oral presentation authored by A. Luetkemeyer, S. Rosenkranz, D. Lu, P. Lizak, P. Ive, S. Swindells, C. Benson, B. Grinsztenj, I. Sanne, D. Havlir, and F. Aweeka.

 

Tolerability among HIV-infected persons of three months of once-weekly rifapentine + INH (3HP) vs. 9 months of daily INH (9H) for treatment of latent tuberculosis infection: The PREVENT TB Study (TBTC Study 26/ACTG 5259).

This is an oral presentation authored by T. Sterling, C. Benson, N. Shang, J. Miro, B. Grinsztejn, R. Chaisson, A. Lucchetti, J. Sanchez, N. Scott, and M. Villarino.

 

ACTG Underrepresented Populations Committee

Knowledge and perceptions of HIV clinical trials in underrepresented populations in the United States (US).

This is a poster presentation authored by J. Castillo-Mancilla, S. Cohn, S. Krishnan, M. Cespedes, M. Floris-Morre, G. Schulte, G. Pavlov, D. Mildvan and K. Smith.

 

3rd Annual Workshop on Global HIV Clinical Pharmacology Capacity Building and Implementation Research:

The 3rd Annual Workshop on Global HIV Clinical Pharmacology Capactiy Building and Implementation Reserach, jointly sponsored by the University at Buffalo and Northwestern University, will cover a variety of topics in support of strengthening global capacity for clniical pharmacology and implementation research. The workshop features distinguished speakers from Italy, India, Nigeria, Zimbabwe, and the United States and will focus on collaborative approaches to capacity building for HIV/AIDS clinical and transitional pharmacology research.

This is an IAS AIDS 2012 Satellite Session.

 

 HPTN

 

Substained treatment as prevention: continued decreases in unprotected sex and virological suprression after HAART initiation among participants in HPTN 052.

This is an oral poster presentation authored by K. Mayer, L. Wang, IF Hoffman, M. McCauley, X. Li, S. Safren, T. Gamble, J. Talley, L. Cottle, E. Piwowar-Manning, V. Akelo, S. Badal-Faesen, N. Chotirosniramit, NM Fernandes, N. Kumarasamy, J. Makhema, B. Maseko, F. Matchere, N. Nhando, R. Panchia, JH da Silva Pilotto, BR Santos, and MS Cohen.

 

Time-to-ART-Intiation: A Risk Factor Analysis of the HPTN 052 HIV-infected Partners on Delayed Therapy.

This is a poster authored by YQ Chen, SS Ou, J. Eron, MC Hosseinipour, B. Grinsztejn, M. McCauley, T. Gamble, L. Cottle, L. Wang, S. Eshleman, V. Akelo, S. Badal-Faesen, S. Chariyalertsak, S. Godbole, JG Hakim, N. Kumarasamy, J. Kumwenda, J. Makhema, R. Panchia, JH Pilotto, BR Santos, MS Cohen for the HPTN 052 Study Team.

 

Effect of early verses delayed initiation of antiretroviral therapy (ART) on clinical outcomes in the HPTN 052 randomized clinical trial.

This is a presenation authored by B. Grinsztejn, M. Hosseinipour, S. Swindells, H. Ribaudo, J. Eron, YQ Chen, L. Wang, SS Ou, M. Anderson, M. McCauley, T. Gamble, N. Kumarasamy, J. Hakim, J. Kumwenda, J. Pilotto, S. Godbole, S. Chariyalertsak, B. Santos, K. Mayer, S. Eshleman, E. Piwowar-Mannging, L. Cottle, J. Makhema, L. Mills, R. Panchia, I. Sanne, V. Elharrar, D. Havlir, MS Cohen for the HPTN 052/ACTG Study Team.

 

The cost-effectiveness of treatment as prevention: analysis of the HPTN 052 trial.

RP Walensky, EL Ross, N. Kumarasamy, R. Wood, F. Noubary, AD Paltiel, YM Nakamura, S. Godbole, M. Hosseinipour, JG Hakim, J. Kumwenda, J. Makhema, V. Akelo, R. Panchia, I. Sanne, MC Weinstein, E. Losina, KH Mayer, B. Grinsztejn, J. Pilotto, S. Chariyalertsak, B. Santos, YQ Chen, L. Wang, X. Li, M. McCauley, T. Gamble, E. Piwowar-Mannging, L. Cottle, I. Hoffman, J. Eron, J. Gallant, S. Swindells, T. Taha, K. Nielsen-Saines, D. Celentano, M. Essex, V. Elharrar, D. Burns, G. Seage, MS Choen, and K. Freedburg.

 

One year of counseling supported buprenorphine-naloxone treatment for HIV prevention in opiate dependent injection drug users showed efficacy in reducing opiate use and injection frequency: HPTN 058 in Thailand and China.

This is a poster presentation authored by D. Metzger, D. Donnell, D. Celentano, A. Aramrattana, B. Jackson, Y. Shao, S. Rose, B. Dye, G. Lucas, M. Chawarski, G. Beauchamp, T. Liu, D. Burns, R. Chen, K. Davenny, K. Shin, L. Wei, L. Fu, H. Jianhua, Z. Hong, R. Yuhua, M. Jun, M. Motevalli, L. Walshe, H. Redinger, C. Busch, J. Ko, M. Xing, Y. Li, L. Shuaifeng, J. Hung, and K. Wei.

 

Lessons Learned from Implementing a Black Caucus into HPTN 061: Demonstrated Community Engagement.

This is a poster presentation authored by S. Fields, L. Wilton, C. Watson, J. Lucas, D. Wheeler, and the HPTN 061 Black Caucus.

 

A Study of Perceived Discrimination in Black MSM and its Association with Healthcare Utilization and HIV Testing

This is a poster presentation authored by R. Irvin, L. Wilton, G. Beauchamp, L. Wang, and S. Buchbinder.

 

An Evolving Concentrated Epidemic: Comparison of Socioeconomic, Behavioral and Biological Factors among Newly Diagnosed, Previously Diagnosed and HIV-Uninfected Black Men Who Have Sex With Men in 6 US Cities (HPTN 061).

This is a presentation authored by KH Mayer, L. Wang, B. Koblin, C. Mao, S. Mannheimer, M. Magnus, C. del Rio, S. Buchbinder, L. Wilton, V. Cummings, C. Watson, S. Griffith, and D. Wheeler for the HPTN 061 Protocol Team.

 

Nonadherence to HIV Testing Guidelines and Late HIV Diagnosis is Common Among US Black Men Who Have Sex with Men (MSM).

This is a presentation authored by S. Mannheimer, L. Wang, HV Tieu, C. del Rio, S. Buchbinder, L. Wilton, S. Glick, V. Cummings, and KH Mayer on behalf of the HPTN 061 Study Team.

 

Sexual Networks and HIV Risk among Black Men Who Have Sex with Men (BMSM) in the US (HPTN 061).

This is a poster presentation authored by HV Tieu, TY Liu, L. Wang, C. Mao, P. Gorbach, S> Hussen, S> Buchbinder, K. Mayer, L. Wilton, C. Kelly, V. Elharrar, G. Phillips, S. Griffith, V. Cummings, B. Koblin, and C. Latkins for the HPTN 061 Study Group.

 

The high prevelance of incaceration among Black men who have sex with men (BMSM): associations and implications.

This is a poster presentation authored by R. Brewer, M. Magnus, L. Wang, T. Liu, and K. Mayer on behalf of the 061 Study Team.

 

Sociocultural and Psychological Factors as Predictors of HIV Sexual Risk Behavior in Black Men Who Have Sex with Men (MSM) from 6 US cities.

This is a poster presentation authored by L. Wilton, S. Shoptaw, JK Williams, R. Irvin, L. Nelson, T. Penniman, D. Wheeler, K. Mayer, C. Watson, V. Elharrar, P. Sullivan, L. Wang and V. Cummings.

 

Differences in psychological, social, substance use and HIV sexual risks between urban Black Men who have Sex with Men Only (BMSMO) and Black Men who have Sex with Men and Women (BMSMW).

This is a poster presentation authored by T. Penniman Dyer, L. Wilton, N. Harawa, L. Wang, SS Ou, V. Cummings, and S. Shoptaw on bhealf of the HPTN 061 Study Team.

 

Direct and Indirect Concurrency Among a Cohort of Low-Income US Women: Data from HTPN 064 (The Women's HIV SeroIncidence Study).

This is a poster presentation authored by S. Hodder, A. Adimora, C. Golin, I. Kuo, C. del Rio, S. Mannheimer, D. Haley, J. Wang, J. Hughes, L. Johnson-Lewis, S. Eshleman, L. Soto-Torres, and J. Justman on behalf of the HPTN 064 Study Team.

 

High Rates of Post-Traumatic Stress Disorder among a Cohort of Low-Income US Women in High HIV Prevalen e Communities: Data from HTPN 064 (The Women's HIV SeroIncidence Study).

This is a poster presentation authored by CE Golin, D. Haley, J. Wang, I. Kuo, J. Hughes, J. Justman, C. del Rio, A. Adimora, S. Mannheimer, W. El Sadr, L. Soto-Torres, and S. Hodder on behalf of the HPTN 064 Study Team.

 

Correlates of individual and partner sexual rsik behaviors in US women participants in HPTN 064 WOmen's HIV SeroIncidence Study (ISIS)

This is a poster presentation authored by J. Justman, C. Golin, J. Hughes, J. Wang, I. Kuo, S. Hodder, D. Haley, C. del Rio, W. El-Sadr, S. Mannheimer, and L. Soto-Torres on behalf of the HPTN 064 Study Team.

 

Substance Use Patterns and Changes Over Time in a Cohort of High-Risk Heterosexual Women in the United States: Datat from the HPTN 064 Women's HIV SeroIncidence Study (ISIS).

This is a poster presentation authored by I. Kuo, S. Hodder, C. Golin, J. Wang, J. Hughes, J. Justman, D. Haley, C. del Rio, W. El-Sadr, S. Mannheimer, and L. Soto-Torres on bhealf of the HPTN 064 Study Team.

 

Reported Behavior Change and Attitudes on Prevention Studies Among Newark, NJ HPTN 064 Participants: Results of Exit Interview.

This is a poster presentation authored by S. Swaminthan, R. Deshields, E. Rios, C. Torres, K. Abbass, and SL Hodder.

 

Clinician Practices and Attitudes Regarding Early Antiretroviral Therapy in the US: Baseline Results from HPTN 065.

This is a poster presentation authored by A. Kurth, K. Mayer, G. Beauchamp, L. McKinstry, J. Farrior, K. Buchacz, G. Simon, J. Zellan, D. Donnell, B. Branson, and W. El-Sadr on behalf of the HPTN 065 Study Team.

 

Linkage-to-Care and ART Adherence Practices at participating sites in HPTN 065 (TLC-Plus) Study.

This is a poster presentation authored by E. Greene, K. Buchacz, T. Gamble, G. Beauchamp, L. McKinstry, A. Wood, E. Telzak, B. Branson, and W. El-Sadr on behalf of the HPTN 065 Study Team.

 

Community Engagement for HPTN 065 (TLC-PLus) study, a community based study evaluating the feasibility of a combination of interventions to prevent HIV transmission in the US.

This is a poster presentation authored by G. King, N. Sista, C. Richards-Clarke, M. Turner, T. Gamble, and J. Lucas on behalf of the HPTN 065 Study Team.

 

HIV testing in six cities using behavioral surveillance data for the TLC-Plus (HPTN 065) study.

This is a poster presentation authored by K. Gray, B. Branson, D. Donnell, G> Beauchamp, X. Hu, Z. Wang, W. El Sadr, and I. Hall on behalf of the HPTN 065 Study Team.

 

Assessing viral suppression amongst HIV patients accessing care in five cities using US HIV surveillance data for the TLC-Plus (HPTN 065) study.

This is a poster presentation authored by D. Donnell, I. Hall, G. Beauchamp, K. Gray, A. Griffin, K. Brady, J. Meyer, N. Benbow, L. Torian, B. Branson, and W. El Sadr on behalf of the HPTN 065 Study Team.

 

HIV Incidence determination in clade B epidemics: a multi-assay approach.

This is an oral presentation authored by O. Laeyendecker, R. Brookmeyer, MM Cousins, C. Mullis, J. Konikoff, D. Donnell, C. Celum, SP Buchbinder, GR Seage, GD Kirk, SH Mehta, J. Astemborski, LP Jacobson, JB Margolick, J. Brown, TC Quinn, and SH Eshleman.

 

Correlates of HIV incidence among Black Men Who Have Sex with Men in 6 U.S. Cities (HTPN)

This is an oral presentation authored by B. Koblin, K. Mayer, S. Eshleman, L. Wang, S. Shoptaw, C. del Rio, S. Buchbinder, M. Magnus, S. Mannheimer, T.-Y. Liu, V. Cummings, E. Piwowar-Manning, S. Fields, S. Griffith, V. Elharrar, D. Wheller and the HPTN 061 Study Team.

 

Evaluation of a rapid point-of-care test to screen for HIV infection in infants.

This is a poster presentation authored by E. Piwowar-Manning, M. James, L. Johnson-Lewis, J. Sun, D. Hoover, D. Soko, P. Richardson, L. Schopp, P. Katundu, J. Kumwenda, N. Kumwenda, TE Taha, and SH Eshleman.

 

Linkage-to-Care and ART Adherence Practices at participating sites in HPTN 065 (TLC-Plus) Study

This is a poster presentation authored by E. Greene, K. Buchacz, T. Gamble, L. mcKinstry, G. Beauchamp, B. Branson, and W. El-Sadr.

 

HPTN (presentation roadmap) at the XIX International AIDS Conference Washington, DC.

 

 HVTN

 

​AIDS Vaccine Symposia 02: Lessons from Clinical Trials - Comparative immunogenicity of HIV vaccine candidates in the HVTN.

This is an oral presentation presented by Nicole Fraham.

 

Vaccination with MVA/HIV induces differential recruitment of monocyte subsets into the circulation and monocyte-specific transciptional programs.

This is an oral presentation authored by Andersen-Nissen E, Zak DE, Hensley TR, Adams DJ, Hu X, Sato A, Elizaga ML, Goepfert PA, Robinson HL, Aderem A, and McElrath MJ.

 

rAd5 prime/NYVAC-B boost regimen is superior to NYVAC-B prime/rAd5 boost regimen for both response rates and magnitude of CD4 and CD8 T-cell responses.

This is an oral presentation authored by Bart PA, Huang Y, Frahm N, Karuna S, Allen M, Kochar N, Chappuis S, Gaillard J, Grahjam B, and Pantaleo G.

 

Phase 2a Satefy and Immunogenicity Testing of DNA and Recombinana Modified Vaccinia Ankara Virus Cavvines Expressing Virus-Like Particles.

This is an oral presentation authored by Goepfert PA, Elizaga M, Montefior D, Hural J, DeRosa S, Tomaras G, Sato A, Seaton K, ouerdraogo L, Donastorg Y, Cardinali M, Lama J, Baden L, Keefer M, McElrath J, Kalams S, and Robinson H.

 

Multiple Antibody Specificities, including gp41, V1V2, and V3 Elicited in the Phase II Multiclade (A,B,C) HIV-1 DAN Prime, Multiclade (A,B,C) rAd5 Boost Vaccine Trial.

This is an oral presentation authored by Williams WB, Jones K, Krambrink A, Grove D, Liu P, Yates NL, Moody MA,a Ferrari G, Pollara J, Moddie Z, Morgan CA, Liao H, Montefiori DC, Ochsenbauer C, Kappes J, Hammer S, Mascola J, Koup R, Corey L, Nabel G, Gilbert P, Churcyard G, Keefer M, Graham BS, Haynes BF, and Tomaras GD.

 

First-in-human phase 1 clinical trial of a recombinant vesicular stomatitis virus (rVSV)-based preventive HIV-1 vaccine.

This is a poster presentation authored by Fuchs JD, Frank I, Kochar N, Elizaga M, Allen M, Carter DK, Frahm N, Kalams SA, Mulligan M, Sheets R, Pensiero M, Clarke D, and Eldridge for the NIAID HVTN.

 

DNA and recombinant adenovirus serotype 35 and 5 preventive HIV-1 vaccines with Env A inserts elicit cross-clade binding and V1V2 antibodies.

This is a poster presentation authored by Fuchs JD, Morgan C, Bart PA, Kochar N, Frahm N, Swann E, Gilbert P, De Rosa S, Graham B, Nabel G, Liao HX, Haynes B, Tomaras G and the NIAID HVTN.

 

Feasibility of recruiting-high-risk women in the US for HIV vaccine efficacy trials (HVTN 906).

This is a poster presentation authored by Koblin B, Metch B, Morgan C, Novak R, Swann E, Metzger D, Lucy D, Dunbar D, Graham P, Madenwald T, Escamilla G, Frank I on behavlf of the HVTN 906 study team.

 

Screen failure in phase 1 HIV clinical trials in Soweto, South Africa: an opportunity for care.

This is a poster presentation authored by Laher F, Mamba M, otwombe K, and Gray GE.

 

rAd5/NYVAC-B is superior to NYVAC-B/rAd5 and is dependent on rAd5 dose for neutralizing antibody responses against HIV-1.

This is a poster presentation authored by Montefiori D, Huang Y, Karuna S, Allen M, Kochar N, Chappuis S, Gaillard J, Tomaras G, Graham B, Bart PA, and Pantaleo G.

 

DNA plasmid HIV vaccine design, number of doses, participant gender, and body mass index affect T-cell responses across HIV vaccine clinical trials.

This is a poster presentation authored by Morgan C, Jin X, Yu X, Keefer MC, De Rosa S, Metch B, Kublin J, and the NIAID HVTN.

 

Rapid development of cross-clade neutralizing antibody responses in human volunteers after priming with clade B gp120/gp140 protein and boosting with clade C gp140 protein.

This is a poster presentation authored by Spearman P, Tomaras G, Montegiori D, Huang Y, Ahmed H, Elizaga M, Hural J, McElrath J, Ouedraogo L, Pensiero M, Butler C, Kalams S, Overton ET, Barnett S, and the NIH/NIAID HVTN.

 

HIV vaccine trial safety and retention among 18-20 year olds in the HVTN 503/Phambili study support the inclusion of adolescents in future trials.

This is a poster presentation authored by Volk JE, Hessol NA, Gray GE, Kublin JG, Churchyard G, mlisana K, Nchabeleng M, Buchbinder SP, and Bekker-LG.

 

 Using an internet consumer marketing strategy to reach men who have sex with men for participation in a preventive HIV vaccine clinical trial.

This is a poster presentation authored by Voytek C, Jones KT, Curtis B, Fiore D, Dunbar D, Frank I, Metzger DS, and the NIAID HVTN.

 

 HVTN Satellite Sesions:

HIV Vaccine Efficacy Trials: What does it take?

Presented by M. McCluskey, B. Snow, G. Alter, N. Frahm, J. Kim, M. Sobiesczyk, J. Manyard.

 

Efficacy Trials in Desgin: A global perspective.

Presented by Larry Corey.

 

HIV Vaccine Trials in the PrEP Era.

Presented by S. Buchbinder and S. Hammer.

 

 IMPAACT

 

Association of Tenofovir Disoproxil Fumarate with Neonatal Growth (P1025) - Poster Exhibition

Ransom CE, Huo Y, Patel K , Scott GB, Watts H, Williams PL, Siberry G, Livingston E, for the P1025 Team of the International Maternal Pediatric Adolescent AIDS Clinical Trials Group.

 

Tenofovir Disoproxil Fumarate (TDF) Pharmacokinetics (PK) with Daily Dosing in the First Week of Life (HPTN 057) - Oral presentation

K. Nielsen-Saines, M. Mirochnick, N Kumwenda, E. Joao, R. Kreitchmann, J. Pinto, B. Santos, T. Parsons, T. Taha, L. Mofenson, P. Sato, B. Kearney, M.G. Fowler and the HPTN 057 Protocol Team.

 

Raltegravir (RAL) Safety and Efficacy in Patients 2 to 18 Years of Age through Week 48 (P1066) - Oral Presentation

Sharon Nachman, Edward Acosta, Nan Zheng, Hedy Teppler, Brenda Homony, Xia Xu, Carmelita Alvero, Edward Handelsman, Carol Worrell, Bobbie Graham, Elizabeth Petzold, Andrew Wiznia and the P1066 Group.

 

Size and Decay of the Resting CD4+ T Cell Latent HIV Reservoir in Early-Treated Infants (P1030) - Poster Exhibition

D. Persaud, P.E. Palumbo, C. Ziemniak, M. D. Hughes, C.G. Alvero, K. Luzuriaga, R. Yogev, E.V. Capparelli, and E.G. Chadwick.

 

Pharmacokinetics, Safety, and Efficacy of Dolutegravir (DTG; S/GSK1349572) in HIV-1 Infected Adolescents: Preliminary analysis from IMPAACT 1093 (P1093) - Oral Abstract Session

Rolando Viani, Edward Acosta, Nan Zheng, Carmelita Alvero, Ellen O’Gara, Rohan Hazra, Elizabeth Petzold, Barb Heckman, Debra Steimers, Ivy Song, Steve Piscitelli, Andrew Wiznia on behalf of the P1093 study team.

 

Predictors of Tuberculosis Disease in HIV-infected and HIV-exposed uninfected children from Southern Africa: IMPAACT P 1041 study (P1041/DAC646) - Poster Exhibition

Maritz ER , Liu L , Montepiedra G , Mitchell CD , Madhi SA, Bobat R, Violari A, Ogwu A, Hesseling AC , and Cotton MF.

 

Association between nevirapine-resistant HIV-variants and antiretroviral treatment outcomes in single-dose nevirapine exposed infants (P1060) - Poster Exhibition

Deborah Persaud, Jane Lindsey, Carrie Ziemniak, Ya Hui Chen, Leila Khaki, Susan Eshleman and Paul Palumbo.

 

HIV-1 viral kinetics among in utero and intrapartum infected infants in NICHD HPTN 040/ PACTG 1043 (HPTN 040/PACTG 1043) - Poster Exhibition

Karin Nielsen-Saines, Heather Watts, Yvonne Bryson, Valdilea Veloso, James Bethel, Jiahong Xu, Margaret Camarca, Mariza Morgado, Ruth E. Dickover, Esau C. Joao, Jose Henrique Pilotto, Glenda Gray, Jack Moye, Mark Mirochnick, Lynne Mofenson and the NICHD HPTN 040 Protocol Team.

 

Comparison of HIV-Genotyping Results Obtained from Next-generation Sequencing of Plasma and Dried Blood Spot Samples (P1060) - Oral Abstract Session

Carrie Ziemniak, Ya-Hui Chen, Paul Palumbo, and Deborah Persaud.

 

 INSIGHT

 

Predicting the risk of cancer during HIV infection: the role of inflammatory and coagulation biomarkers

This is an oral presentation authored by AH Borges, MJ Silverberg, D. Wentworth, A. Grulich, G. Fatkenheuer, R. Mitsuyasu, G. Tambussi, C. Sabin, J. Neaton, and JD Lundgren (presenting) for the INSIGHT SMART, ESPRIT, and SILCAAT Study Groups.

 

Suboptimal self-reported ART adherence associated with certain prtease inhibitors and virologic rebound in the SMART study

This is a poster presentation authored by S. Mannheimer, JL O'Connor, EM Gardner, AR Lifson, SE Esser, E. Telzak, and A. Phillips for the INSIGHT SMART Study Group (TUPE066).

 

Factors associated with elevated D-dimer levels in HIV-positive individuals

This is a poster presentation authored by A. Borges, JL O'Connor, A. Phillips J. Baker, M. Vjecha, M. Losso, H. Klinker, G. Lopardo, I. Williams, and J. Lundgren for the INSIGHT SMART, ESPRIT, and SILCAAT Study Groups (WEPE094)

 

 MTN

 

Rectal Microbicides: Making HIV Prevention Gel.

This is a satellite session presented in partnership with AVAC, IRMA, and the IPM.

 

Choice Matters: Expanding the Method Mix of ARV-Based Prevention for Women in 2012 and Beyond.

This is a satellite session presented in partnership with AVAC, IRMA, and the IPM.

 

Microbicides: The Road Ahead.

This is a satellite session presented by Jeanne Marrazzo which in addition to MTN is being organized by the Population council, IPM, CONRAD, and IRMA.​

Digg Delicious Facebook Newsvine Reddit StumbleUpon Twitter Email Link

share:

SiteMap

sitemap:

© HIV/AIDS Network Coordination